DNAsolve‎ > ‎WHAT WE DO‎ > ‎


DNAsolve...making better drugs a reality

Sunil Chada, Ph.D
Sunil Chada, Ph.D has over 25 years of successful international management experience in the biotechnology and pharmaceutical industries, including an industry-sponsored research institute. Dr. Chada has worked in the areas of drug discovery, preclinical drug safety and efficacy, pharmacology and translational medicine, as well as the regulatory aspects of drug development in the US, Europe and Japan.

Dr Chada has expertise in the development of numerous types of pharmaceutical and biotechnology products, including  engineered cells (CAR- and TCR-engineered T cells) gene therapies (including replication-defective adenovirus, retrovirus, lentivirus, adeno-associated virus and oncolytic adenovirus), 
small molecules, liposome-encapsulated nanoparticles and human immunotherapies as personalized medicines. He has published over 120 peer-reviewed scientific papers, review articles and book chapters in the scientific literature. Much of his career has focused on translational medicine, moving product candidates from desktop to clinic, with a particular emphasis on oncology products.  He was involved with or lead translation of >15 product candidates into clinical trials, a number of which are in late stage clinical trials.

Dr Chada has been responsible for multiple biologics and small molecule drugs, including therapies for the treatment of cancers, infectious diseases, hemophilia and autoimmune disorders. These drugs have been tested clinically in patients with lung, breast, prostate, colorectal, melanoma, esophageal and head and neck cancers in addition to patients with HIV and genetically inherited cancer. In these roles, he was responsible for the nonclinical sections for US NDA and BLA submissions and for international regulatory submissions for the initiation of clinical trials.

During his career, Dr. Chada has served on various industry, academic and governmental advisory boards, including the Special Emphasis Panel of the NCI RAID program, NCI SBIR/ STTR review committees, 
advisory committees to MD Anderson Cancer Center and Rice University and as an advisor/ reviewer for the Dutch and Italian government National Cancer Institutes. He has also served a Chairperson for the American Society of Gene Therapy annual conferences in addition to editorial duties for multiple scientific journals.  More recently, Dr. Chada was invited to serve as a member of the CPRIT (Cancer Prevention and Research Institute of Texas) Commercialization Council and as an Advisory Board Member to the  Experimental Therapeutics Program at the University of Oklahoma Health Sciences Center.  He also served as Special Advisor to the Chief Scientific Officer of the $3B MD Anderson Cancer Center Moonshots Program.  
Sunil Chada,
Aug 2, 2017, 8:40 AM